Register for our free email digests:
Latest From CureTech Ltd.
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.
BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Humana Inc.
- Senior Management
Bruce D Broussard, Pres. & CEO
Brian A Kane, SVP, CFO
Roy A Beveridge, MD, SVP, CMO
- Contact Info
Phone: (502) 580-1000
500 West Main St.
P.O. Box 1438 Louisville, KY 40202
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.